3 results about "Treatment level" patented technology

The invention discloses a liver targeted peptide-recombinant human endostatin fusion protein, and a preparation method and application thereof. According to the invention, 19 amino acids in the N terminal conserved I region of plasmodium circumsporozoite protein (CSP) capable of being specifically combined with hepatocyte surface receptor--heparan sulfate proteoglycan (HSPG) are fused to the carboxyl terminal of a novel human endostatin (nhES), the amino terminal of which is added with 9 amino acid sequences (MGGSHHHHH), by a gene engineering method, thereby obtaining the liver targeted peptide-recombinant human endostatin fusion protein (ES-CPS). The fusion protein is easy to purify, can be specifically used in livers for inhibiting neovascularization in a targeted mode, enhances the local concentration of the medicine in the foci, reduces the consumption to the whole body, and lowers the toxic or side effect. The invention provides an idea and scientific reference for clinically developing medicines for treating liver cancers by targeted inhibition of neovascularization, and has huge scientific meanings and practical value for further enhancing the liver cancer treatment level in China.